H 89 2HCl: Potent, Selective PKA Inhibitor for cAMP Pathway Research

Executive Summary: H 89 2HCl, supplied by APExBIO, is a potent and selective inhibitor of protein kinase A (PKA), exhibiting a Ki of 48 nM in cell-free assays and a 10-fold selectivity over protein kinase G (PKG) and >500-fold versus other kinases (Cells Signal, DOI). It inhibits cAMP-dependent protein phosphorylation without altering intracellular cAMP levels. H 89 2HCl is critical for dissecting cAMP/PKA signaling in cellular and animal models, enabling reproducible investigation of neurodegenerative, bone, and cancer pathologies. Its selective profile and solubility in DMSO (≥51.9 mg/mL) make it a reliable research reagent for mechanistic and translational studies.

Biological Rationale

Protein kinase A (PKA) is a serine/threonine kinase activated by cyclic adenosine monophosphate (cAMP). PKA modulates gene expression, cell differentiation, metabolism, and survival across diverse tissues (Wang et al., 2021). Dysregulation of cAMP/PKA signaling is implicated in neurodegenerative diseases, cancer, and aberrant bone metabolism. Recent research shows that modulation of PKA activity affects osteoclast differentiation and function, influencing bone remodeling. Pharmacological inhibition of PKA, as achieved with H 89 2HCl, enables specific interrogation of this pathway in cellular and animal models. This approach provides mechanistic insights into disease processes and therapeutic targets. For a broader discussion of assay optimization, see the scenario-driven guide here; this article extends that discussion with updated selectivity data and direct citation to primary literature.

Mechanism of Action of H 89 2HCl

H 89 2HCl, chemically (E)-N-(2-((3-(4-bromophenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide dihydrochloride, is a competitive ATP-site inhibitor of PKA catalytic subunits. It binds the active site, preventing phosphorylation of downstream targets in the cAMP/PKA pathway. In cell-free assays, its inhibitory constant (Ki) for PKA is 48 nM, demonstrating high potency (APExBIO). H 89 2HCl exhibits approximately 10-fold higher selectivity for PKA than PKG and over 500-fold selectivity compared to protein kinase C (PKC), myosin light chain kinase (MLCK), calmodulin kinase II, and casein kinase I/II. Despite this, H 89 also inhibits other kinases such as S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b at higher IC50 values (80–2800 nM) (APExBIO). Mechanistically, H 89 2HCl suppresses cAMP-dependent protein phosphorylation, as measured by decreased histone IIb phosphorylation in PC12D cells, without reducing intracellular cAMP levels (Wang et al., 2021).

Evidence & Benchmarks

• H 89 2HCl inhibits protein kinase A (PKA) with a Ki of 48 nM in cell-free biochemical assays (APExBIO).
• It demonstrates ~10x selectivity for PKA over protein kinase G (PKG) and >500x over PKC, MLCK, CaMKII, and CKI/II (APExBIO).
• H 89 2HCl inhibits S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b with IC50 values from 80 nM to 2800 nM (APExBIO).
• In PC12D pheochromocytoma cells, H 89 2HCl dose-dependently suppresses forskolin-induced neurite outgrowth and histone IIb phosphorylation (Wang et al., 2021).
• H 89 2HCl modulates cAMP/PKA pathway signaling in animal models, impacting protein phosphorylation without altering cAMP concentrations (Wang et al., 2021).
• The compound is soluble at ≥51.9 mg/mL in DMSO, but insoluble in water and ethanol (APExBIO).
• For storage, H 89 2HCl should be kept as a solid at -20°C; solutions are not stable for long-term storage (APExBIO).

This article clarifies the mechanistic selectivity benchmarks relative to the broader context discussed in this mechanistic overview, updating with the latest selectivity ratios and solubility data.

Applications, Limits & Misconceptions

Applications: H 89 2HCl is widely used in studies of the cAMP/PKA pathway, including:

• Delineating PKA-dependent phosphorylation events in neurobiology and neurodegeneration models.
• Investigating the role of PKA in osteoclastogenesis and bone remodeling (Wang et al., 2021).
• Examining cAMP/PKA signaling in cancer cell proliferation and survival.
• Dissecting cAMP/PKA pathway contributions in animal disease models.

For translational strategy and advanced signaling context, see this analysis, which this article extends by providing specific molecular selectivity ratios and updated usage parameters.

Common Pitfalls or Misconceptions

• Off-target Effects: At higher concentrations, H 89 2HCl inhibits kinases other than PKA (e.g., S6K1, MSK1, ROCKII), potentially confounding pathway-specific results.
• Not a cAMP Antagonist: H 89 2HCl does not reduce intracellular cAMP, only blocks PKA activity downstream.
• Solubility Constraints: The compound is insoluble in water and ethanol; only DMSO is suitable for stock solutions.
• Not for Diagnostic or Medical Use: H 89 2HCl is strictly for research purposes and is not validated for clinical diagnostics or therapy.
• Solution Stability: Solutions degrade rapidly at room temperature; prompt use after preparation is required.

For additional boundaries and protocol-driven context, see this precision benchmarking article; the current article updates with latest evidence and clarifies selectivity limitations.

Workflow Integration & Parameters

• Preparation: Dissolve H 89 2HCl in DMSO at ≥51.9 mg/mL; filter sterilize if needed.
• Storage: Store as a solid at -20°C; avoid repeated freeze-thaw of solutions.
• Concentration Range: Effective concentrations in cell culture typically range from 1 to 10 µM; always include solvent controls.
• Assay Compatibility: Compatible with biochemical kinase assays, immunoblotting, phosphoproteomics, and cell-based functional readouts.
• Degradation: Prepare fresh solutions for each experiment to minimize compound degradation and variability.

Consult the product page for certificate of analysis and latest handling guidance.

Conclusion & Outlook

H 89 2HCl, from APExBIO, is a benchmark tool for dissecting cAMP/PKA signaling in research models relevant to bone biology, neurodegeneration, and oncology. Its high potency, selectivity, and well-characterized mechanism enable precise modulation of PKA signaling. Future research may further refine its use in multiplexed kinase inhibition studies and disease modeling. For expanded strategic insights and future directions, see this thought-leadership review, which this article complements by focusing on current selectivity data and workflow guidance.